Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — H1 2022 Earnings Presentation
32 slides from Cosmo Pharmaceuticals Nv's earnings presentation, Jul 28, 2022
Slide 1: Delivering Innovation + Improving Lives: Half-Year Results 2022
DELIVERING INNOVATION + IMPROVING LIVES HALF-YEAR RESULTS 2022 JULY 28, 2022
Slide 2: Safe harbour
Safe harbour This presentation may include forward-looking statements Cosmo’s business and risks following any potential for that are based on our management’s beliefs and delays in the development programs for its products. No assumptions and on information currently available to our assurance can
Slide 3: Agenda
01 Introduction Alessandro Della Chà - CEO 02 H1 2022 Key Events & Products Update Alessandro Della Chà - CEO 03 2022 Financial Review Niall Donnelly - CFO 04 2022 Key Priorities & Guidance Alessandro Della Chà - CEO Cosmo Pharmaceuticals | Half Year Results 2022 3
Slide 4: Introduction
INTRODUCTION ALESSANDRO DELLA CHÀ CEO Cosmo Pharmaceuticals | Half Year Results 2022 4
Slide 5: Who we are
Who we are Cosmo is a pharmaceutical company which develops and manufactures innovative products in the fields of: Gastroenterology HealthTech Dermatology Gastrointestinal (GI) diseases Artificial Intelligence applications Skin and Hair loss in endoscopy Inflammatory Bowel Disease (IBD) Colorectal c
Slide 6: Our business model is based on 3 pillars
Our business model is based on 3 pillars to increase opportunities and decrease risks 01 Development and manufacturing of OWN PRODUCTS Bear no cost Have a + for a commercial lean and simple infrastructure cost base 02 Distributed through our selective STRONG PARTNERSHIPS This enables Cosmo to Increa
Slide 7: Overview
Founded Listed on Six Mkt cap (June 2022) since 2007 CHF Overview1 1997 COPN 821m Total employees Male Female Different nationalities 43 focusing on AI 292 60% 40% 15 12% 27% S,G&A R&D 61% Production & Logistics 1as at June 2022 Cosmo Pharmaceuticals | Half Year Results 2022 7
Slide 8: H1 2022 Key Events and Product Update
H1 2022 KEY EVENTS AND PRODUCT UPDATE ALESSANDRO DELLA CHÀ CEO Cosmo Pharmaceuticals | Half Year Results 2022 8
Slide 9: Delivering the record best half year revenue performance
Delivering the record best half year revenue performance €28.4m €41.5m H1 2022 H1 2021 Revenue increase of 46.1% H1 2022 vs H1 2021 Cosmo Pharmaceuticals | Half Year Results 2022 9
Slide 10: Solid performance in H1 2022
Solid performance in H1 2022 Ferring submitted the NDA for Cortiment® in Japan. Application has US trial showed 50% reduction in missed colorectal polyps using been accepted by PMDA. Review is expected to last approximately a GI Genius™ versus standard colonoscopy year Significant increase in contra
Slide 11: Legacy business continues to grow
LEGACY BUSINESS CONTINUES TO GROW Cosmo Pharmaceuticals | Half Year Results 2022 11
Slide 12: Lialda – Mezavant – Mesavancol
Lialda® – Mezavant® – Mesavancol® Mesalamine Mesalamine Tablets Supplied (Millions) Revenue in Eur (Millions) 160,0 €13.0m 13,00 156.1m 12,80 11% growth 155,0 in revenues due to 12,60 increase in volumes 150,0 12,40 in US and Japan 12,20 145,0 12,00 11,80 €11.7m 140,0 139.3m 11,60 11,40 135,0 11,20
Slide 13: Uceris – Cortiment
Uceris® – Cortiment® Budesonide Budesonide Tablets Supplied (Millions) Revenue in Eur (Millions) 4,50 14,0 3.9m 4,00 €12.0 12,0 3,50 10,0 Cortiment® 3,00 Major milestones received 2,50 8,0 €8m 2,00 1.9m reaching cumulative net 6,0 sales of €100m 1,50 4,0 1,00 €2.8m Next €8m expected at reaching €200
Slide 14: Revenue from drug development and manufacturing on behalf of third parties
Revenue from drug development and manufacturing on behalf of third parties 7 €5.8m €6.0m 6 5 4 3 2 1 0 H1 2021 H1 2022 Cosmo Pharmaceuticals | Half Year Results 2022 14
Slide 15: New products are delivering
NEW PRODUCTS ARE DELIVERING Cosmo Pharmaceuticals | Half Year Results 2022 15
Slide 16: Winlevi is the #1 most prescribed branded topical acne product in the U.S.
WINLEVI® is the #1 most prescribed branded topical acne product in the U.S. Unique prescribers U.S. gross market Prescriptions (TRX) generated on a cumulative basis to date 10,000 $5bn >258,000 Launched in the U.S. by Potential to receive high double- Sun Pharma in Nov. 2021 digit royalties and up t
Slide 17: GI Genius: Compatible with all major brands of endoscopic equipment
GI GENIUS™: Compatible with all major brands of endoscopic equipment World market XXXXXX >60m annual colonoscopies In April 2021 GI Genius™ was approved by the FDA U.S. XXXXXX HIGH ADENOMA DETECTION RATE 52.2% >19m CAN SIGNIFICANTLY REDUCE THE decrease in annual colonoscopies INCIDENCE OF INTERVAL C
Slide 18: Significant leap in signed contracts
Significant leap in signed contracts Commercial negotiations ongoing in US with potential clients representing 6,000 endoscopic towers (20% of the U.S. market) Endoscopic towers in the U.S. Contracted devices signed by Medtronic with clients in >30,000 U.S. & EU >850 Devices ordered by Medtronic Del
Slide 19: Top U.S. hospitals that have installed GI Genius
Some of the top U.S. hospitals who have already installed GI Genius™ Beth Israel (BIDMC) Einstein Medical, 01 Harvard, Boston 08 Pennsylvania Stanford University, Hospital Corporation 02 California 09 of America (HCA) Cornell University, US Veterans Affairs, 03 New York 10 Virginia New York Universi
Slide 20: Development pipeline progress
DEVELOPMENT PIPELINE PROGRESS Cosmo Pharmaceuticals | Half Year Results 2022 20
Slide 21: Update on clinical development pipeline
Listed on Six since 2007 Update on clinical development pipeline COPN CB-03-10 CB-01-33 (Cortexolone 17α-valerate- Breezula® (Colesevelam) 21-propionate) (Clascoterone solution) Phase I study started in patients Preparing to start the Phase 3 trial in Completing formulation & IP protection with adva
Slide 22: HY 2022 Financial Review
HY 2022 FINANCIAL REVIEW NIALL DONNELLY CFO Cosmo Pharmaceuticals | Half Year Results 2022 22
Slide 23: HY 2022: Financial Highlights
HY 2022: Financial Highlights Growth in revenue, EBITDA and operating profit, delivering positive cashflow from operations HY22 Revenue HY22 Profit before tax €41.5m up 46.1% (HY2021: €28.4m) €9.0m (HY2021: €4.7m Loss before tax) HY22 EBITDA HY22 Net cashflow from operating activities €14.9m up 338.
Slide 24: Product revenue distribution, new products generating revenue
Product revenue distribution, new products generating revenue Positive impact on our financial performance €m - Revenue by product H1 2021 vs. H1 2022 Revenue split by product H1 2022 14,00 12,95 Winlevi Lumeblue Contract 13,5% 11,69 0,1% Manufacturing 12,00 12,9% 10,00 9,36 Other 4,2% 8,00 5,37 GI
Slide 25: Events after close of H1 2022, Key Priorities & Guidance
EVENTS AFTER CLOSE OF H1 2022 KEY PRIORITIES & GUIDANCE ALESSANDRO DELLA CHÀ CEO Cosmo Pharmaceuticals | Half Year Results 2022 25
Slide 26: Expanded partnership with Sun Pharma for Winlevi
Expanded partnership with Sun Pharma making Winlevi® available to more patients around the world In July, announced the signing of addendums to the License and Supply Agreements with Sun Pharma expanding the territory to include Japan, Australia, New Zealand, Brazil, Mexico and Russia Sun Pharma wil
Slide 27: New partnership for Winlevi with 3SBio in Greater China
New partnership for WINLEVI® with 3SBio in Greater China US$ 6.5m License Agreement for Winlevi® in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”) Upfront payment 3SBio will have the exclusive right to develop and commercialize Winlevi® in Greater China Cosmo will be the exclusive sup
Slide 28: Huge market potential in Greater China
Huge market potential in Greater China >95% of Chinese are suffering from Proportion of patients suffering from acne scars ranges from 3% to 7%, causing physical and psychological acne in various degrees1. damage to the patients. >100 million young people aging • Acne treatment rate at very low leve
Slide 29: Key priorities for 2022 and beyond
Key priorities for 2022 and beyond 01 02 ENSURE THAT GI GENIUS™ CONTINUES ENSURE THAT WINLEVI® CONTINUES TO PERFORM BY PROVIDING TO PERFORM IN THE US MARKET BY MEDTRONIC WITH ALL THE NECESSARY PROVIDING SUN WITH ALL THE SUPPLY AND SUPPORT NECESSARY SUPPLY AND SUPPORT 03 04 PROGRESS THE CB-03-10 PHAS
Slide 30: Strong financial position as of June 2022
Strong financial position as of 30 June 2022 €219.0m Cash and fund investments €54.5m €39.4m €312.9m Treasury Shares Equity stakes in and loans to listed companies Total Cosmo Pharmaceuticals | Half Year Results 2022 30
Slide 31: FY 2022 financial guidance reaffirmed
FY 2022 financial guidance reaffirmed Revenue and operating profit growth into 2022 Total Revenue driven by continued €90m – €100m performance of legacy products and increase in Operating Profit new products revenues €20m – €25m Cosmo Pharmaceuticals | Half Year Results 2022 31
Slide 32: Thank you
THANK YOU Mr. Alessandro Della Chà, CEO adellacha@cosmopharma.com Mr. Niall Donnelly, CFO ndonnelly@cosmopharma.com Cosmo Pharmaceuticals N.V. Riverside II Sir John Rogerson’s Quay Ms. Hazel Winchester, Head of IR Dublin 2, Ireland hwinchester@cosmopharma.com investor.relations@cosmopharma.com
Cosmo Pharmaceuticals — H1 2022 Earnings Presentation on 6ix